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Tiroid Kanser Genomiğinin Güncel Klinik Atlası: ThyroSeq v.2 Yeni Jenerasyon
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Abstract
The next-generation sequencing technology allows high out-put genomic analysis. An innovative assay in thyroid cancer,
ThyroSeq® was developed for targeted mutation detection by next generation sequencing technology in fine needle
aspiration and tissue samples. ThyroSeq v.2 next generation sequencing panel offers simultaneous sequencing and detection
in >1000 hotspots of 14 thyroid cancer-related genes and for 42 types of gene fusions known to occur in thyroid cancer.
ThyroSeq is being increasingly used to further narrow the indeterminate category defined by cytology for thyroid nodules.
From a surgical perspective, genomic profiling also provides prognostic and predictive information and closely relates to
determination of surgical strategy. Both the genomic analysis technology and the informatics for the cancer genome data
base are rapidly developing. In this paper, we have gathered existing information on the thyroid cancer-related genes involved
in the initiation and progression of thyroid cancer. Our goal is to assemble a glossary for the current ThyroSeq genomic panel
that can help elucidate the role genomics play in thyroid cancer oncogenesis.
Keywords: Thyroid cancer, next generation sequencing, ThyroSeq

Öz
Tiroid nodüllerinde kanser teşhisi ve tiroid kanserlerinin prognostik değerlendirilmesi için geliştirilmiş en güncel yöntem DNA
dizinleme teknolojisine dayalı ThyroSeq® testidir. Bu test ince iğne aspirasyon materyalinde genetik profilleme yaparak tiroid
kanserinin tetiklenmesinde ve gelişmesinde rol alan mutasyon ve genetik değişiklikleri tespit etmektedir. Bu makalede bu
test ile tespit edilebilen genetik değişikliklere konu olan genlerin yapı ve fonksiyonlarını kısaca tanımlıyoruz. Tiroid kanseri
onkogenezine bir ölçüde ışık tutan bu test için sözlük görevi tutan bir makale sunulmaktadır.
Anahtar kelimeler: Tiroid kanseri, yeni jenerasyon dizinleme, ThyroSeq

Introduction

of particular tumor biology beyond conventional
definitions. Molecular pathology is the new paradigm
in cancer diagnosis and prognostication. Thyroid cancer
develops and progresses through accumulation of genetic
alterations, which does serve as important diagnostic,
prognostic, and predictive biological markers (2). Nextgeneration sequencing technology allows high out-put

Thyroid nodules are prevalent in the general population.
Most thyroid nodules are benign and the clinical challenge
is to accurately identify those nodules that are malignant
and need to be surgically removed (1). Moreover, the extent
of initial surgical treatment requires better understanding
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genomic analysis. An innovative assay in thyroid cancer ThyroSeq® - was developed for targeted mutation detection
by next generation sequencing technology in fine needle
aspiration and tissue samples. ThyroSeq v.2 next generation
sequencing panel offers simultaneous sequencing and
detection in >1000 hotspots of 14 thyroid cancer-related
genes and for 42 types of gene fusions known to occur
in thyroid cancer (3). ThyroSeq is being increasingly used
to further narrow the indeterminate category defined by
cytology for thyroid nodules. From a surgical perspective,
understandably this provides prognostic and predictive
information as it relates to determination of surgical
strategy. Both the genomic analysis technology and the
data collection for the cancer genome atlas are rapidly
developing.
This paper reviews basic genomic information on 23
thyroid cancer-related genes involved in thyroid cancer.

We have detailed information in regards to the location,
and function of these genes in normal thyroid cells. We
also report gathered information as to the consequences
mutations to these 23 genes can have on thyroid cancer
initiation and progression. Our goal is to provide a detailed
glossary for ThyroSeq mutation panel.

Molecular Markers of ThyroSeq Next-Generation
Sequencing Panel
B-RAF
The B-RAF gene, located on chromosome 7q34, encodes
B-RAF serine-threonine kinase, which functions as an
intracellular effector of the RAS/MAPK signaling cascade
(Figure 1). This is one of the three isoforms of the RAF
serine-threonine kinase and the predominant isoform found

Figure 1. MAPK/ERK pathway
*This pathway begins with a mitogenic stimulus binding to a receptor tyrosine kinase, activating it. This triggers a cascade of protein activation, beginning with RAS and
culminating with ERK. Once ERK is phosphorylated, it enters the nucleus and influences transcription, increasing expression of tumor-promoting genes and decreasing
expression of tumor-suppressing genes. MAPK signaling can also be stimulated by genetic alterations in proteins RET and NTRK
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in thyroid follicular cells. In wild-type forms of this gene,
the B-RAF protein is activated through binding of a RASGTP protein complex with the B-RAF’s RAS binding domain
along with simultaneous conformational changes in the
protein. Once activated, the B-RAF protein phosphorylates
the next protein in the signal cascade-MEK and ERK. The
protein’s function contributes to the RAS/MAPK pathway’s
role in cell proliferation, migration, and differentiation (4,5).
The most common B-RAF mutation found in thyroid
carcinomas is a point mutation at residue 600 involving
a substitution from valine to glutamate (V600E). This
mutation results in the constitutive activation of the B-RAF
protein and subsequently the RAS/MAPK pathway. The
activation of the B-RAF protein seems to be caused by a
disruption of the hydrophobic interactions between its
activation loop and the ATP binding site. In wild-type B-RAF,
these hydrophobic interactions help maintain the protein in
an inactive conformation. When disrupted, B-RAF remains
in an active, catalytic conformation. This results in the
constitutive phosphorylation of its downstream targets (4).
The B-RAF V600E point mutation is most prevalent in
papillary thyroid carcinomas (PTC)-the most common form
of well differentiated thyroid carcinoma-found in 45% of
PTC cases. Though it is rare in follicular variants of thyroid
carcinoma, B-RAF is an ideal genetic marker for use in a
thyroid cancer sequencing panel. It is found in all forms of
thyroid carcinoma and seems to play a very important role
early in tumorigenesis as a driver mutation (4,5,6).

RAS
The RAS genes consist of a family of highly homologous
isoforms: K-RAS, N-RAS, and H-RAS. Located on
chromosomes 12p12.1, 11p5.5, and 1p13.1 respectively, all
three genes encode G-proteins located on the inner surface
of the cell membrane. These proteins help convey signals
from receptor tyrosine kinases (RTKs) to the pathways RAS
regulates: RAS/MAPK and PI3K/AKT signaling cascades
(Figure 2). Once bound to GTP, the RAS proteins proceed
to activate the RAS/MAPK pathway. The RAS-GTP complex
quickly becomes inactive as a result of the protein’s innate
GTPase activity (7).
Point mutations in the RAS gene are the most common
mutations. Mutations in codons 12 and 13 lead to an
increased affinity for GTP. Mutations in codon 61 lead to
inactivation of the RAS protein’s innate GTPase function.
Overall, these mutations result in the constitutive
activation of the RAS protein and thus the activation of
the downstream signaling pathways it regulates, a critical
step in thyroid tumorigenesis. Thyroid carcinoma has been
associated with mutations in all three isoforms of the
RAS genes, though it seems the more prevalent mutated
isoform is that of N-RAS. However, the actual pattern of
isoform frequencies in thyroid carcinoma remains unclear
(4,7).

RAS mutations occur with variable frequency in all types
of thyroid follicular-derived tumors. RAS point mutations
are most common in follicular thyroid carcinoma (FTC),
occurring in 40-50% of tumors, as well as in poorly
differentiated and anaplastic thyroid carcinoma (PDC and
ATC). It is more infrequent in PTCs, occurring in about 10%
of tumors. The prevalence of RAS mutations in thyroid
carcinoma make it a viable genetic marker as well as a
useful prognostic tool, given that, studies suggest it may
increase the potential for malignant transformation and
tumor progression (7).

CTNNB1
The CTNNB1 gene, located on chromosome 3p21, encodes
a cytoplasmic protein known as β-catenin. This protein
plays several important roles in the cell. It is involved in
E-cadherin mediated cell to cell adhesion, found primarily
in adherens junctions. It is also an intermediate in the Wnt
signaling pathway. Once activated by proteins upstream
in the pathway, β-catenin is able to accumulate in the
cytoplasm and eventually is translocated into the nucleus.
In the nucleus, the protein works with T-cell factor/
lymphoid enhancing factor (TCF/LEF) to modulate gene
expression (8,9).
When β-catenin is not activated, free cytoplasmic levels
are kept low through ubiquitin-proteasome degradation
(Figure 3). However, point mutations in exon 3 of CTNNB1
confer added stability to the protein and thus inhibit the
degradation of β-catenin. This results in the accumulation
and localization of β-catenin in the cytoplasm and nucleus
of the cell and the constitutive activation of its targeted
genes (ex: Cyclin D1, C-MYC, C-JUN) (8,10,11).
Mutations in CTNNB1 are most commonly found in PDC
and ATC but not in well differentiated forms. It is typically
described as a late event in thyroid cancer progression, but
dysregulation of β-catenin has been shown to contribute to
tumor proliferation (10,11).
CTNNB1 can serve as a useful marker for PDC and ATC.
Its involvement in the Wnt pathway contributes to its
viability as a marker, given this pathway is constitutively
active in 50% of PDC and ATC and it is involved in the
dedifferentiation process of thyroid carcinoma (Figure 4)
(10). This gene is thus a useful diagnostic marker as well as
prognostic tool to determine the progression of the cancer
and its propensity to spread.

NTRK1
The NTRK1 gene, which is located on chromosome 1q2122, encodes the neurotrophic RTK-1, also known as TrkA. It
is a high affinity receptor for nerve growth factor-β (NFG-β)
that provides instructions for the growth and development
of nerve cells. It also induces the proliferation of a number of
cell types, such as lymphocytes and keratinocytes. Once it is
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bound to NFG-β, NTRK1 dimerizes and autophosphorylates
its five tyrosine residues, which then act as binding sites for
several target proteins such as RAS and PI3K. By activating
these proteins, NTRK1 subsequently activates the RAS/
MAPK and PI3K/AKT signaling cascades, thus mediating
NGF effects on the proliferation and differentiation of cells
(12,13).
Mutations in the NTRK1 gene are frequently found in PTC.
These mutations involve chromosomal rearrangements
between NTRK1 and at least three other identified genes:
TPM3, TPR, and TFG. The chimeric oncogenes that are
formed (TRK oncogenes) encode constitutively active RTKs.
It remains active due to the fact that its kinase domain
and the tyrosine binding sites are preserved in the chimeric
oncogene. The only portion that is lost is a portion of
its extracellular domain. It seems that the extracellular

domain may contain important regulatory elements. This
provides constant activation of the protein signals for cell
proliferation, contributing to PTC (12,13).
About 60% of PTC carry chimeric oncogenes created
through chromosomal rearrangement. Though RET
rearrangement and not NTRK1 is the most prevalent
chimeric oncogene detected in PTC, thyroid epithelium
seems to have a propensity for chromosomal
rearrangements. That fact, along with NTRK1 association
with pathways implicated in thyroid carcinoma (RAS/
MAPK and PI3K/AKT) make this gene a viable marker for
diagnostic and prognostic purposes. Nevertheless, further
investigation is necessary to better understand its role in
thyroid carcinogenesis (13,14).

Figure 2. PI3K/AKT pathway
*The pathway begins with an extracellular stimuli activating a receptor tyrosine kinase, triggering the activation of RAS followed by PI3K. Activated PI3K catalyzes the conversion
of phosphatidylinositol (4,5)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3), a step that is regulated by PTEN. PIP3 activates the 3-phosphoinositidedependent protein kinase 1, which targets and phosphorylates AKT. Phosphorylated AKT then enters the nucleus, where it increases the expression of tumor-promoting genes.
Activated AKT also produces changes in the cytoplasm by activating mTOR and thus promoting translation. AKT can also phosphorylate glycogen synthase kinase 3-β (GSK3-β),
inactivating the protein. GSK3-β inhibition results in a concomitant stimulation of β-catenin, allowing it to enter the nucleus and increase expression of tumor-promoting genes
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NTRK3
Another member of the neurotrophic tyrosine receptor
kinase family, NTRK3 encodes a RTK with a high affinity for its
ligand neurotrophin-3. The gene is located on chromosome
15q25. Once bound, NTRK3 autophosphorylates and
proceeds to phosphorylate target proteins primarily involved
in the RAS/MAPK and PI3K/AKT signaling pathways.
Primarily expressed in the central nervous system, NTRK3
is involved in cell proliferation and differentiation as well as
neuronal cell processes (14,15).
The mutation of NTRK3 observed in thyroid carcinomas
is a chromosomal rearrangement involving ETV6, a gene
encoding a transcription factor from the ETS transcription
factor family. This particular oncogenic fusion involves the
fusion of exons 1-4, the SAM domain, of ETV6 and exons
12-18, the tyrosine kinase domain, of NTRK3. This results
in the constitutive activation of the RTK. It is this constant

activation that contributes to thyroid carcinogenesis
(15,16).
Chromosomal rearrangements of the NTRK genes are
uncommon in sporadic PTC, only occurring in about 2%
of cases. However, there is higher prevalence of these
chimeric oncogenes in pediatric and radiation-related PTC,
with the majority of ETV6-NTRK3 fusions demonstrating
the follicular variant of PTC. Mutations resulting in RAS/
MAPK activation in radiation-related PTC tend to differ
from those found in sporadic PTC as there tends to be
more chromosomal rearrangements than point mutations
(15,16).

RET
The RET gene is a proto-oncogene that is highly expressed
in parafollicular C-cells. Located on chromosome 10q11.2,
this gene encodes a RTK that is involved in the RAS/MAPK

Figure 3. CTNNB1/TERT signaling
*Dysregulation of telomerase is an almost universal feature of cancer, either through genetic amplification of the gene’s own locus or through crosstalk activity with other
signaling pathways. In this pathway mutations to the promoter site of TERT (C228T and C250T) increase the transcription of TERT through the creation of consensus binding
sites for ETS transcription factors. Constitutive action of the MAPK pathway due to B-RAF or RAS mutations leads to upregulation of TERT from ETS transcription binding activity.
TERT also possess a role as a transcriptional modulator of the Wnt-β-catenin signaling pathway. Wnt stimulation at the plasma membrane leads to increased levels of β-catenin
in the cytoplasm, and translocation to the nucleus. In the nucleus β-catenin forms a complex with TERT and the Wnt transcription factor BRG1. Once formed this complex binds
to the promoters of Wnt target genes regulating the expression of these oncogenes
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signaling pathway. The RET protein responds to signals
from the cell’s environment and then proceeds to activate
itself through autophosphorylation. Once activated, the
RET protein elicits changes within the cell often involving
cell proliferation and development (4,17).
Chromosomal rearrangements involving RET represents one of
the most common causes of PTC. At least 11 rearrangement
variants have been isolated but the most common translocations
are RET/PTC1 and RET/PTC3. The aforementioned
rearrangements are intrachromosomal paracentric inversions
and account for the vast majority of variants found in PTC.
These rearrangements result in a constitutively active RET
protein, leading to activation of the RAS/MAPK pathway and
driving thyroid carcinogenesis (17,18).
The RET/PTC1 rearrangement involves interaction between
RET and the H4 gene. This particular rearrangement
is the dominant type in sporadic PTCs. The RET/PTC3
rearrangement involves interaction between RET and the
ELE1 gene. This particular rearrangement is the dominant
type in radiation-related PTCs, which tend to be more
aggressive and exhibit a higher frequency of chromosomal
rearrangements (4,17).

AKT1
AKT1 codes for the AKT1 kinase, one member of a
family of homologous isoforms. Located on chromosome
14q32.322, AKT1 kinase helps regulate cell growth and
survival as well as the process of apoptosis, mainly through
interaction with signaling pathways like PI3K/AKT. The
protein contains a pleckstrin homology domain, making
it a target for phospholipids generated by PI3K activity.
Once activated through phosphorylation, AKT1 binds to
chaperone proteins and proceeds to phosphorylate its
downstream effectors. Through this pathway, activated
AKT1 is able to inhibit apoptosis and induce cell growth in
thyroid cells (19).
Activation of AKT1 is known to promote thyroid tumorigenesis
in Cowden’s syndrome (CS). It is the overexpression and
overactivation of AKT1, rather than mutation of the AKT1
gene, that contributes to the pathogenesis of sporadic
thyroid cancers, particularly in follicular thyroid cancers (FTC).
In FTCs, activation of AKT1 kinase and the localization of
the protein in the nucleus promotes the PI3K/AKT pathway,
contributing to tumor invasion and metastasis. It seems
that overexpression of AKT1 is capable of promoting cell

Figure 4. Thyroid hormone signaling
*Follicular cells contain thyroid stimulating hormone receptors (TSHR). Once bound to the hormone TSH, this G-protein coupled receptor generates the second messenger
cyclic AMP. This second messenger activates protein kinases that trigger signal cascades responsible for thyroid cell proliferation and function. TSH stimulation of TSHR also
leads to iodide transport into the cell via the sodium iodide symporter. This iodide is oxidized and then bound to tyrosine residues on thyroglobulin (TG), a process catalyzed by
thyroperoxidase. This primed form of TG can then be cleaved through proteolysis in the cell to generate the thyroid hormones T3 and T4
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proliferation, sensitization to TSH, and inhibiting apoptosis,
but it is not sufficient to transform thyroid cells by itself
(19,20).
This alteration in AKT1 occurs in about 15% of metastatic
thyroid cancers, while also occurring in small fractions
of ATCs and FTCs. Studies have shown that there is
an association between AKT1 activation and tumor
aggressiveness. This association with metastasis in thyroid
carcinoma was found in both PTC and FTC. However, the
aggressiveness seen is likely attributed to a combination of
genetic alterations rather than solely on dysregulation of
AKT1 activity (19,20,21).

TERT
The TERT gene, located on chromosome 5p15.33, encodes
the protein telomerase reverse transcriptase. It is the
catalytic subunit of the telomerase enzyme and determines
telomerase activity. The TERT subunit associates with a RNA
component TERC as well as additional components to form
the telomerase enzyme. Telomerase serves an important
role in synthesizing and maintaining telomeres, which
helps prolong the life of cells in the body. When telomeres
become too short, apoptosis is triggered in the cell. As a
result, telomerase activity is highly regulated and expressed
at very low levels in most tissues in the body (22).
Dysregulation of telomerase is an almost universal feature
of cancer, with over 90% exhibiting overexpression of the
enzyme. This imparts cancer cells with an infinite capability
to divide. The up-regulation of TERT that is seen could be the
result of epigenetic deregulation or genetic amplification
of the gene’s locus (Figure 3). Other factors contributing
to the dysregulation of TERT expression involve changes
in transcription factors that target the TERT gene. Such
factors include TP53 and the ETS transcription factors.
Both are disrupted in thyroid carcinoma as TP53 is often
mutated and ETS transcription factors are stimulated
by several oncogenes including RAS. These associations
indicate a relationship between an up-regulation of TERT
expression and the transformation of thyroid cells. One
recently discovered mechanism has been mutations in the
TERT promoter, the most important regulatory element of
telomerase activity (22,23).
These promoter mutations, C228T and C250T, seem to
increase the transcription of TERT, likely through the
creation of consensus binding sites for ETS transcription
factors. Promoter mutation C228T is the most common
one found in thyroid carcinoma with no overlaps reported
in the mutations. There seems to be a higher prevalence
of TERT promoter mutations in more advanced forms of
thyroid carcinoma like ATC. Studies have shown a strong
association between TERT promoter mutations and B-RAF
or RAS mutations as well. The evidence uncovered so
far shows that mutations in the TERT promoter seems to
represent a late stage genetic event in tumorigenesis as

well as an indicator of aggressiveness given its prevalence
in ATC (24,25).

GNAS
The GNAS gene provides instructions for the stimulatory
α-subunit of heterotrimeric G protein complexes. The
gene is located on chromosome 20q13.3. This subunit
stimulates the activity of adenylate cyclase and controls
the production of several hormones that help regulate
the activity of the endocrine glands such as the thyroid
gland. Mutations in GNAS are often detected at codons
201 and 227. These mutations result in the constitutive
activation by impairing GTP hydrolysis. This in turn results
in the constitutive activation of the cyclic AMP (cAMP)
cascade. The increase in cAMP levels results in thyroid cell
proliferation and increased thyroid hormone production.
Despite this disruption in function, these mutations are
almost never malignant (20,26).
Activating mutations of GNAS has been shown to
overactivate thyroid stimulating hormone receptor (TSHR)
signaling. This often leads to benign, hyperfunctional
follicular thyroid adenomas (FTAs). Mutation of GNAS is
also the main cause for autonomously functioning thyroid
nodules. Studies show that mutations in GNAS resulting
in overactivation of the G protein alpha subunit leads to a
hyperfunctioning thyroid. Serving as a potential marker for
benign thyroid nodules, GNAS does not seem to serve as a
driver of thyroid carcinogenesis. However, it seems likely that
this disruption in thyroid function in conjunction with other
genetic alterations plays a role in thyroid carcinoma (26).

PIK3CA
PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase
catalytic subunit alpha, is a gene located on chromosome
3q26.3. It encodes the p110 alpha subunit of the PI3K
kinase. This particular subunit is the catalytic subunit and
is responsible for the kinase function of the protein. PI3K
plays a very important role in the PI3K/AKT signaling
pathway, one of the major pathways implicated in thyroid
carcinoma. As part of this signaling pathway, PI3K helps
regulate cell proliferation, motility, adhesion, and cell cycle
progression. The pathway begins with signals transmitted
from the environment to the inside of the cell through
RTKs. These RTKs then engage PI3K, recruiting the protein
to the cell membrane and generating phosphatidylinositol3,4,5-triphosphate (PIP3). PIP3 acts as a second messenger,
recruiting protein kinases phosphoinositide-dependent
protein kinase 1 (PDK1) and AKT to the membrane. Once
activated via phosphorylation, these kinases target their
downstream effectors, producing concomitant changes to
cell growth and differentiation. This pathway is regulated
by the PTEN lipid phosphatase, which dephosphorylates
PIP3 and thus shuts off the PI3K/AKT pathway (27).
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The PI3K pathway is frequently activated in thyroid
carcinoma and studies have reported the overexpression
of PIK3CA in FTC and ATC. The most common PIK3CA
mutations observed with oncogenic effects tend to cluster
around exons 9 and 20. These mainly somatic mutations
result in the constitutive activation of PI3K. Consequently,
this leads to overactivation of the PI3K/AKT pathway and
thyroid tumorigenesis. Genetic alterations have been found
in all differentiated stages of thyroid carcinoma. However,
it seems to be the most frequent in ATC, occurring in
about 24% of ATC cases. Given the occurrence of PIK3CA
mutations in all stages of thyroid carcinoma, it supports the
implication of the PI3K/AKT signaling pathway in both the
initiation and progressive dedifferentiation of the disease
(27,28,29).

PTEN
PTEN, phosphatase and tensin homolog, encodes a
phosphatase enzyme found in almost all tissues in the
body. Located on chromosome 10q23.3, PTEN plays an
important role in the PI3K/AKT pathway. Once activated
via phosphorylation, PTEN works to terminate the signaling
pathway through its phosphatase activity. It converts PIP3
into PIP2and shuts off the PI3K/AKT pathway and reduces
the recruitment of kinases PDK1 and AKT. As a result, this
protein helps regulate cell proliferation and differentiation
(28,29).
A tumor suppressor gene, PTEN is found mutated
frequently in thyroid tumors. Point mutations, deletions,
and promoter methylation in PTEN have been reported in
thyroid carcinoma, particularly undifferentiated ones like
ATC. Overall, studies have shown that PTEN inactivation is
a critical step in thyroid tumor progression. This is evident
in the fact that PTEN is downregulated or absent in highly
malignant thyroid carcinoma like ATC, though mutations
have been found in more differentiated forms. PTEN
downregulation has been reported in about 37% of FTCs.
Ultimately, this inactivation results in the overactivation of
the PI3K/AKT signaling pathway, resulting in rampant cell
proliferation (28,29,30).
PTEN mutations tend to be most frequent in ATC, with an
occurrence in about 15% of cases. Germline mutations of
PTEN is also a leading cause of CS, a disorder that can result
in benign and malignant tumors. Individuals with CS have
a 10% risk of developing thyroid cancer. This association
between CS and PTEN further supports its role in thyroid
tumorigenesis (27,29,30,31).

TSHR
The TSHR gene, located on chromosome 14q31, encodes
the TSHR. This G protein-coupled receptor spans the
membrane of follicular cells in the thyroid. Once activated
by thyroid stimulating hormone (TSH), TSHR produces

corresponding effects in the cell via second messengers
like cAMP. This intracellular signaling plays an important
role in thyroid cell proliferation and maintenance of thyroid
function (Figure 4). Deregulation of TSHR seems to play an
important role in thyroid carcinogenesis (20).
Studies have shown an association between high levels
of TSH and the development of thyroid nodules. The
overactivation of TSHR, whether through activating
mutations in TSHR or GNAS, has also been shown to lead
to hyperfunctional FTA. However, these tumors are rarely
malignant, suggesting that TSHR could serve a dichotomous
role - protecting against malignancy of thyroid tissue but
also promoting carcinogenesis likely when activated by
other oncogenic alterations. Mouse models have shown
that TSHR is required for thyroid carcinogenesis. It is
still uncertain whether this supports TSHR’s role in the
initiation of thyroid carcinoma or it is simply due to the
TSHR-dependent generation of thyroid cells from which
carcinogenesis initiates (20,32,33).
Epigenetics has shown to play an integral part in the
role of TSHR in thyroid carcinoma. Hypermethylation of
the TSHR promoter has been frequently found in thyroid
carcinoma, while it is unmethylated in normal and benign
thyroid tumors. This epigenetic silencing is most prevalent
in PTC, with a frequency of 34-59%. Epigenetic silencing via
hypermethylation is also prevalent in more undifferentiated
forms of thyroid carcinoma. Studies have also shown
a strong association with B-RAF mutations in PTC. This
relationship supports the theory that TSHR silencing is a
secondary genetic event in thyroid carcinogenesis and not
essential for the initiation of thyroid carcinoma (32,33).
The silencing of TSHR not only contributes to the
development of thyroid carcinoma, but it desensitizes the
thyroid tumors to radioiodine therapy through its interaction
with sodium iodide symporter (NIS) in iodide uptake. The
suppression of TSHR hinders the cancer cells’ ability to
concentrate iodine. Though no silencing mutations have
been found thus far, it seems that methylation of TSHR
serves as a marker for thyroid malignancy (33).

TG
The TG gene located on chromosome 8q24, encodes the
prohormone TG. This protein, found in thyroid follicular
cells, acts as a precursor for the thyroid hormones, serving
as the matrix from which they are produced. It acts as a
protein storehouse and when the thyroid hormones are
needed, TG is altered and broken down to release the
needed hormones. Tyrosine residues on the TG protein
are iodinated, priming the protein for modification into
the thyroid hormones T3 and T4 (Figure 4). The synthesis
of TG is regulated by TSH, with TSH serving to stimulate
production (34).
Mutations in TG have been reported in thyroid carcinoma.
They tend to be more frequently found in differentiated
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thyroid carcinomas, like PTC. The majority of PTCs with
a mutation in TG tend to also carry a mutation in one
of the genes in the MAPK signaling pathway. Though
rarely mutated, TG does seem to contribute to the
malignancy of the cancer. As the cancer dedifferentiates,
the expression of TG seems to decrease, with it becoming
absent in ATC. These genetic changes do not seem to
be sufficient to initiate thyroid carcinogenesis, but
the hormonal imbalance produced seems to aid in its
progression (34,35).
Changes in TG are more commonly associated with
dyshormonogenesis, occurring with a frequency of 25%.
Individuals with the disorder tend to develop goiters, often
due to chronic stimulation by TSH. Studies have shown that
individuals with these dyshormonogenic goiters and TG
mutations have an increased risk of developing aggressive
forms of thyroid carcinoma.
TG also serves as a tool for monitoring thyroid cancer
recurrence and metastasis after treatment and
thyroidectomy. Serum TG levels are carefully monitored and
upon stimulation by TSH, if levels rise too high it serves as
a strong indicator of metastases. Such an association helps
support the role of TG dysregulation in the development of
thyroid carcinoma (35,36,37,38).

PAX8/PPARγ
A chromosomal rearrangement found in thyroid carcinoma
is that between the genes PAX8 and PPARγ, PAX8
encodes a transcription factor that is essential for normal
thyroid development. The PPARγ gene encodes a nuclear
receptor part of the PPAR subfamily. This receptor forms
heterodimers with retinoid X receptors and helps regulate
the transcription of several genes, playing a major role in
adipogenesis and lipid metabolism (3,39).
This rearrangement is the result of a translocation between
chromosome regions 2q13 and 3p25. Highly expressed
in thyroid follicular cells, it seems this fusion protein plays
a role in thyroid tumorigenesis. The exact mechanism is
still unknown. Some studies show that PAX8/PPARγ has
a dominant negative effect on wild type PPARγ, which is
believed to act as a tumor suppressor. The fusion protein
contains the transcriptional regulatory domains of both
proteins. As a result, it is capable of modulating their
respective downstream pathways, usually targeting PAX8responsive promoters (39,40).
PAX8/PPARγ is most frequently found in FTCs, with
an occurrence rate of about 30%, and occurs rarely
in the follicular variant of PTC. The presence of this
rearrangement has no major impact on the prognosis of
thyroid carcinoma. Though still much remains unknown
about this chromosomal rearrangement, evidence points to
its potential as an oncoprotein and genetic driver of thyroid
carcinoma (4,39,40).

IGF2BP3/IMP3
The IGF2BP3 gene is located on chromosome 7p11.2,
and encodes for the insulin-like growth factor-2 (IGF2) mRNA-binding protein 3. IGF2BP3 is a RNA-binding
protein consisting of two RNA-recognition motifs in its
N¬-terminal part and four KH homology domains in the
C-terminal region. Its primary function is as a translational
activator of the IGF-2 gene, while also functioning as a
post-transcriptional regulator of cell proliferation, and
differentiation during embryogenesis. It is important to note
that IGF2BP3 is a member of the highly conserved IGF2BP
family of mRNA-binding proteins along with IGF2BP1 and
IGF2BP2. As a member of the IGF2BP family IGF2BP3 shares
a high amount of similarity to the other three members at
the amino acid level but differs in terms of its expression.
IGF2BP3 is abundantly found in all tissues during embryonic
stage, but it’s expression in normal mature tissue is confined
to the placenta and reproductive tissue (41,42,43).
IGF2BP3 has been the member of the IGF2BP family to
be most associated with various cancer types such as
lung, ovarian, pancreatic, and colorectal. Its role in tumor
progression has been suggested to be by promoting cell
growth, proliferation and resistance to ionic radiation via
an IGF-2 dependent manner. Recent studies have found
IGF2BP3 to play a role in increasing the invasive potential
of tumor cells in vitro (42,43).
Due to the high transcript levels of IGF2BP3 in neoplastic
cells and near undetectable presence in most adult tissue,
it’s been suggested as a potential biomarker. Through the
use of immunoassays, its expression has been exclusively
observed in malignant thyroid cancers of follicular origin,
with a small portion of classical PTC, and was observed in
59% of cases for poorly differentiated thyroid carcinoma
variants. However, through the use of reverse transcription
polymerase chain reaction (RT-PCR) and qRT-PCR assay,
it was demonstrated that IGF2BP3 was overexpressed in
thyroid carcinoma tissue when compared to benign thyroid
lesions. IGF2BP3’s overexpression in thyroid carcinoma, its
near undetectable levels in adult tissue, and its potential to
distinguish between benign and malignant tissue make it
an excellent candidate for the thyroid cancer sequencing
panel (41,44,45,46).

KRT7/KRT20
The KRT7 and KRT20 genes both belong to the keratin
gene family, which consists of 54 functional genes. The
KRT7 gene can be found in type 2 cluster on chromosome
12, while the KRT20 gene is located in the type 1 cluster
on chromosome 17. The protein products of these genes
are subdivided into type 1 and type 2 based on their
molecular weights. KRT7 and KRT 20 both encode for
cytokeratin proteins that are intermediate filament forming
proteins exclusively found in epithelial tissue. The filaments
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are formed from the heterodimer pairing of type 1 and
type 2 cytokeratin proteins in equimolar amounts. The
intermediate filaments created by cytokeratin proteins
aid in forming the structural framework of epithelial cells,
regulate cell size, growth, division, as well as protection
against mechanical stressors (46,47).
Adenocarcinomas compromise the largest group of
human epithelial malignancies and can occur in different
organs. KRT7 and KRT20 along with the other members
of the keratin gene family have been utilized as diagnostic
markers to determine the origin tissue, due to the
characteristic cell-type, differentiation and functional
status-dependent expression pattern of cytokeratin in
epithelial cells. In most adenocarcinomas, the expression
levels of KRT7 and KRT20 are variable and thus are often
screened for together (47).
Current literature on KRT7/KRT20 combined screening of
thyroid neoplasms is scarce. Almost all thyroidal tumor’s
expression levels for KRT7 and KRT20 have been found to
be positive and negative, respectively. In fact, one study
looked into the immunohistochemical profile of 43 different
types of primary and metastatic thyroid neoplasms. They
found that excluding anaplastic carcinomas, 79% of thyroid
tumors and 94% of metastatic thyroid carcinoma cases
reacted positively with the antibody. While the study found
a positive result for KRT7, none of the thyroid tumors or
their metastases reacted at all to the KRT20 antibody. A
second retrospective study examined 153 thyroid carcinoma
samples for KRT7/KRT20 immunohistochemically, and they
found that all papillary carcinomas, follicular carcinomas,
and medullary carcinomas were KRT7 positive and KRT20
negative. Due to the fact that KRT7 has been positively
stained in almost all thyroid neoplasms while KRT20 has
consistently been undetectable, KRT7 and KRT20 are
excellent candidates for the thyroid cancer sequencing
panel (48,49,50).

TP53
The gene TP53 encodes tumor protein p53, located on
chromosome 17p13.1. This protein is a nuclear transcription
factor that functions as a tumor suppressor. P53 contains
three functional domains: a transactivation domain, a DNA
binding domain, and an oligomerization domain. In the
nucleus, it binds directly to DNA in order to help prevent
mutated or damaged DNA from dividing. The protein
either activates other genes to fix any damages or triggers
cell cycle arrest and apoptosis (Figure 5). As a result, this
protein plays a crucial role in regulating cell division and
preventing tumor formation (51).
Any impairment in the function of TP53 can lead to
destabilization of the genome and an accumulation of
mutations. Most changes involve point mutations in exons
5-8, deletions, or inactivation through indirect mechanisms
such as methylation. The now inactivated TP53 protein

becomes unable to bind to DNA and thus is unable to
repair damages that arise in the DNA. The protein, as well
as damages to the DNA, just accumulates in the nucleus.
These type of changes are usually restricted to poorly
differentiated thyroid cancers like ATC, reportedly occurring
in 60% of cases (8,51).
TP53 exhibits tremendous oncogenic potential, as it is
mutated in about 50% of all human cancers. However,
inactivating mutations of TP53 are found in only about 10%
of thyroid carcinomas overall. In well differentiated thyroid
carcinomas, TP53 mutations have a reported relevance
ranging from 0 to 25%. Though it seems other mechanisms
of TP53 inactivation play a role in thyroid carcinogenesis,
as p53 protein is more commonly overexpressed with a
frequency of 11-59% (51,52).

CALCA
CALCA (CALCA-1) gene is a member of the calcitonin
gene family consisting of four known genes, CALCA-1,
CALCA-2, CALCA-3, and CALCA-4 all containing
nucleotide sequence homologies. The CALCA gene
located on chromosome 11 encodes for two separate
peptide hormones. This gene consists of six exons in
which exon 4 and 5 contain the sequences for the
calcitonin and calcitonin gene related peptide (α-CGRP),
respectively. Post-transcriptional processing of the CALCA
gene in thyroid C cells and neural tissue results in tissue
specific production of calcitonin and α-CGRP mRNAs. CT
is a 32 amino-acid peptide hormone with tissue specific
functional roles in the central nervous, skeletal, renal
and gastrointestinal systems. However, CT’s major role
is in calcium and phosphate metabolism. CT modulates
calcium levels by binding with CT receptors to inhibit
osteoclast motility. All of CT’s activities occur through
its binding to the calcitonin receptor, which couples its
binding to the activation of cAMP and PKC signaling
pathways (53,54,55).
Due to the uncharacteristically high concentrations of
calcitonin, serum CT is classically used as a diagnostic
biomarker for MTC. Studies have demonstrated that
preoperative serum CT levels can be strong predictors for
tumor size and remission. Preoperative CT serum levels above
1000 pg/mL correspond to 25.0 mm tumor sizes, while levels
below 100 pg/mL were associated with 3.0 mm tumor size.
Distant metastases are the main cause of death in patients
diagnosed with MTC. Metastasis is initially presented in
50% of MTC cases. Postoperative serum CT levels are an
important procedure in screening for biochemical remission.
CT doubling times have been found to be associated with
progressive or stable disease in 80% of patients. In a study
they found doubling times shorter than 25 months to have
a 94% predictive value of progressive disease along with a
predictive value of 86% for patients with a doubling time
longer than 24 months (53,56,57,58,59).
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CALCA detection studies and procedures involve detection of
this peptide from blood serum. There are limitations to these
assays due to needing stimulation tests, and possible intraassay variation. Some research has found that detection of
CALCA gene transcripts presented higher clinical sensitivity,
specificity, and positive predictive values of 86.67, 97.06, and
92.86%, respectively. In addition to these promising results
their readings mirrored measurements obtainable through
a pentagastrin stimulation test. Due to its tissue specific
production and role in preoperative and postoperative
diagnosing of MTC, CALCA is a viable candidate to include
in the thyroid cancer mutation panel (53,60).

MET
MET, also known as c-MET, encodes a proto-oncogene
that is located on chromosome 7q31. A member of the
RTK family, the MET receptor elicits its effects by binding
to its ligand, hepatocyte growth factor (HGF). Once bound
to HGF, the MET receptor dimerizes and thus becomes
activated and helps promote cell proliferation, survival, and

motility. These effects are largely the result of activation
of MAPK and PI3K pathways through MET signaling. This
process is tightly regulated and any disruption can result in
tumorigenesis (61).
In thyroid carcinoma, what is most commonly seen
is a deregulation of MET, most commonly in PTC.
This deregulation often involves overactivation or
overexpression of MET, which has been shown to
promote tumor growth. This activation can be the
result of activating point mutations often located in the
tyrosine kinase domain, or paracrine signaling due to
increased sensitivity to HGF. The altered MET gene acts
as a mitogenic factor and helps promote cell motility and
invasion (61,62).
Expression levels of MET tend to be low and tightly
regulated in normal thyroids. However, it is amplified in
75% of PTCs, as well as in many FTCs. This overexpression
seems to be secondary to other driver mutations like RAS
and B-RAF. Despite its secondary role, evidence points to
increased MET signaling having a significant role in the
pathogenesis of thyroid carcinoma (62,63,64).

Figure 5. P53 pathway
*Signals of cellular stress, such as DNA damage, triggers activation of p53. Once activated, this nuclear transcription factor travels to the nucleus and binds to DNA, increasing
expression of target genes involved in DNA repair and triggering apoptosis. p53 activity also induces expression of MDM2 as well. MDM2 serves to regulate p53 activity,
inhibiting transcription of p53 and promoting its degradation. Overall, this pathway functions as an auto-regulatory feedback loop
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EIF1AX
This X-linked gene, located on Xp22.12, encodes the
eukaryotic translation initiation factor 1A. This particular
protein is required for the formation of the preinitiation
complex (PIC). It does so by stabilizing the binding of
the initiator tRNA (Met-tRNA) with the 40S ribosomal
subunit and the translation initiation factor eIF2. This is
an integral step in the translation of mRNA into proteins,
as it is required for the binding of the PIC to the 5’ end
of capped mRNA and finding the proper start codon
(65,66).
Mutations in EIF1AX have been found in both PTC
and ATC. The most common sites of mutation are the
N-terminal domain and a C-terminal splice acceptor site
between exons 5 and 6. The C-terminal mutations seem
to be specific to thyroid carcinoma. In PTC, it is rare and
occurs in a mutually exclusive manner, found in only 1-2%
of tumors. But, it is more frequent in ATC, found in 10%
of tumors. It seems that these mutations result in an
overactive EIF1AX, as it has been shown to increase cell
proliferation (65,66,67,68).
EIF1AX mutations tend to coexist with RAS mutations and
other driver mutations of thyroid carcinoma like TP53. This
co-occurrence tends to be found predominantly in poorly
differentiated thyroid carcinomas like ATC. This strong
association suggests that EIF1AX is not sufficient enough
to transform thyroid carcinoma into a malignant form.
Mutations in EIF1AX have also been associated with poor
prognosis in PDCs. The mechanisms of EIF1AX mutation in
thyroid carcinoma are still unclear, especially in terms of its
association with RAS mutations (65,66,67,68).

TTF1
Also known as NK2 homeobox 1, this gene encodes thyroid
transcription factor 1. The TTF1 protein is expressed in the
epithelial cells of the thyroid with a heterogeneous distribution.
As a homeoprotein, it plays an important role in thyroid
development, cell growth, and differentiation. Essential for
thyroid organogenesis, TTF1 helps modulate thyroid function
through its regulation of gene expression in the thyroid,
activating the transcription of thyroid-specific genes like
thyroglobulin (TG) and thyroperoxidase (TPO) (69,70).
The mechanisms by which TTF1 contributes to thyroid
carcinoma still remains unclear. Though the gene is
expressed in thyroid carcinoma, its level of expression
becomes reduced as cell dedifferentiation progresses. This
change in expression could be the result of epigenetic
silencing, likely achieved through hypermethylation and
histone H3 modification. As a result, ATC exhibits the lowest
levels of TTF1. In thyroid carcinoma as a whole it seems
likely that TTF1’s molecular functions, DNA binding, and
transcription activation are probably disrupted. That could
explain why most undifferentiated thyroid carcinomas

have little to no TG or TPO proteins, both targets of TTF1
transcription factor activity (41,42,43).
Germline mutations in TTF1 have also been shown to
play a role in thyroid carcinoma, specifically in PTC. These
mutations seem to promote cell proliferation as well as
activate signaling pathways like PI3K/AKT. The germline
mutations observed in TTF1 have also been associated with
multinodular goiter. This provides further evidence of a
progression from a benign multinodular goiter to malignant
thyroid carcinoma, such as PTC. Given the important role
TTF1 plays in maintaining thyroid architecture and function,
it is not surprising that any abnormalities in the gene and
its product contribute to the development of thyroid
carcinoma (70,71,72).

PTH
The PTH gene encodes a member of the parathyroid family
of proteins and is located on chromosome 11p15.3. This
particular protein binds to the parathyroid hormone receptor
and helps regulate blood calcium and phosphate levels in
the body. Abnormal levels of PTH tend to be associated with
parathyroid diseases, like hyperparathyroidism. However,
there is evidence to suggest a possible link between PTH
and the development of thyroid carcinoma (73).
Primary hyperparathyroidism (PHPT) is a disease that has
been associated with thyroid carcinoma. PHPT results
from an excessive secretion of PTH, which causes an
elevation of calcium in the blood. The most common form
of thyroid carcinoma associated with PHPT is a hereditary
form of MTC known as multiple endocrine neoplasia
type 2A (MEN2A). Carriers of the MEN2A gene with a
mutation at codon 634 concomitantly suffer from PHTP
with a frequency of 10-25%. Such an association provides
evidence to support the role of PTH dysregulation in
thyroid carcinoma (73,74).
Associations between non-medullary thyroid carcinoma
and PHPT have also been reported. With rates ranging from
2-10%, thyroid malignancy seems to coexist with PHPT,
albeit not frequently. A strong relationship has also been
found between ionizing radiation and the simultaneous
development of PHPT and thyroid carcinoma. PTH may
also contribute to the development of thyroid carcinoma
through chromosomal rearrangement with PAD1. This
rearrangement results in an overexpression of cyclin D1
and thus an increase in cell proliferation. Though some
changes to PTH may be the result of metastatic invasion
of the parathyroid by thyroid carcinoma, the evidence
available shows that the role of PTH in thyroid malignancy
overall warrants further investigation (75,76,77).

SCL5A5
The SCL5A5 gene encodes the NIS. NIS is a glycosylated
protein with 13 trans-membrane domains and functions
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to actively transport one I- and two Na+ ions from the
sodium ion gradient established by the Na+/K+ ATPase.
NIS expression at both the transcriptional level and
posttranscriptional level is modulated by the effects of TSH.
TSH causes elevated levels of endogenous cAMP in the
thyroid cells. These cAMP levels play a role in stimulating
several cis-regulatory elements found in the promoter and
upstream enhancer sequences on the SCL5A5 gene on
chromosome 19 (78,79).
The SCL5A5 gene contains an upstream enhancer sequence
(NUE) reported to have both a Pax-8, and cAMP-response
element (CRE) binding sites. Pax-8 and cAMP-response
element modulator (CREM) transcription factors bind to
these cis-elements on the upstream enhancer via cAMPsignaling pathways. These elements are stimulated through
cAMP activation of protein kinase-A (PKA) dependent
pathways in thyroid cells. PKA dependent activation
phosphorylates basic-leucine zipper (B-ZIP) proteins,

CREM, activating transcription factor-1 (ATF-1), and cAMPresponse element binding protein (CREB). Studies have
found that the binding of these transcription factors are
necessary for the NUE’s cAMP induced activity on thyroidal
responsive genes such as TPO, TG, TSHR, and NIS (Figure 6).
While CREB binding is important for SLC5A5 transcriptional
regulation, full SLC5A regulation is not established without
PAX-8 binding. TSH binding increases the expression and
translocation of the anti-oxidative stress factor Ref-1. Ref1 is a nuclear enzyme that reduces Pax-8 and mediates
its binding to the NUE sequence. Impaired translocation
of this nuclear enzyme has been reported in anaplastic,
papillary cell lines as well as in thyroid cancer tissue. TSH
also plays a role in the posttranscriptional regulatory role in
the transport of NIS to the basolateral membrane (78,79).
While no somatic mutations to NIS have yet been identified,
alterations in other genes have been found to be associated
with NIS impairment in differentiated thyroid cancers.

Figure 6. Sodium iodide symporter gene signaling
*The sodium Iodide symporter is a transmembrane protein that plays a crucial role in the uptake of iodine by thyroid cells. The SCL5A5 gene is regulated by the activity of
TSH on the sodium iodide symporter upstream enhancer sequence (NUE). In this pathway TSH binding to TSHR stimulates an increase in cyclic AMP (cAMP) levels in the cell.
Elevated levels of cAMP lead to the activation of protein kinase-A (PKA) dependent p38/MAPK and PKA-cAMP-response element binding protein (CREB) pathways. The p38/
MAPK pathway leads to the recruitment of basic-leucine zipper transcription factors ATF1, and cAMP-response modulator to the nucleus. In the nucleus these transcription
factors bind to the cAMP-response element binding sites in the NUE and activating the SCL5A5 gene. PKA can also directly phosphorylate the cAMP-CREB to directly regulate
cAMP responsive genes such as TSHR, and SCL5A5. Full activation of the SCL5A5 gene is not reached until the PAX-8 transcription factor bindings to the NUE promoter site.
TSH signaling upregulates the transcription and nuclear translocation of the oxidative stress factor Ref-1. Ref-1 activates and recruits PAX-8 to bind to the NUE promoter site,
leading to full SCL5A5 gene activity. Inhibition of SCL5A5 activity can also occur due to the elevated levels of cAMP. These elevated levels can trigger activation of the PI3K
signaling pathway leading to the downregulation of the SLC5A5 gene
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B-RAFV6000E mutations reduce NIS mRNA expression by
inducing the secretion of transforming growth factor-β
(TGF-β). TGF-β acts via the SMAD signaling pathway in an
MEK/ERK independent pathway. RET/PTC rearrangement
impairs the activity of PAX-8 and PKA. Reducing the activity
of these two proteins has been demonstrated to reduce
recruitment of B-ZIP proteins and reduced binding to the
PAX-8 and CRE elements in NUE (79,80,81).
NIS expression has been reported to be reduced in
differentiated thyroid carcinomas. One study found reduced
NIS mRNA expression in PTC tissue samples when compared
to adjacent normal thyroid tissue. NIS expression was also
found to be generally reduced in benign thyroid nodules
compared with adjacent normal tissue, but to a lesser
extent than in PTC tissue samples. It has also been reported
that NIS gene expression is impaired in hypo-functioning
thyroid tumors when compared to normal thyroid tissue.
Quantification of SCL5A5 mRNA levels should be added to
the classical prognostic factors currently used to predict the
outcomes of patients with differentiated thyroid cancer.
SCL5A5 is an excellent candidate for the thyroid cancer
mutation panel (82,83,84).
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